Evaluation of ‘point of care’ devices in the measurement of low blood glucose in neonatal practice

H T Ho, W K Y Yeung, B W Y Young

Background: Low blood glucose in newborns is difficult to detect clinically. Hence a reliable ‘point of care’ device (glucometer) for early detection and treatment of low glucose is needed.

Objective: To evaluate the performance of five readily available glucometers for the detection of low blood glucose in newborn infants.

Method: Glucometrix measurements were taken for newborns with risk factors using a Reflolux S (Boehringer) glucometer. If the initial reading was low (< 2.6 mmol/l), further measurements were taken with two other glucometers (phase I, Advantage and Glucotrend (Roche); phase II, Elite XL (Bayer) and Precision (Abbott)), and plasma glucose was measured in the laboratory (Aerose; Abbott).

Results: Over 10 months, 101 specimens were collected from 71 newborns (57 in phase I; 44 in phase II). The Advantage glucometer usually overestimated blood glucose with a mean difference of 1.07 mmol/l (p < 0.01) at all low glucose ranges. The Glucotrend, Precision, and Elite XL glucometers performed better; the mean differences were not significantly different from the laboratory measured value (0.17 mmol/l (p = 0.37); -0.12 mmol/l (p = 0.13), and 0.24 mmol/l (p = 0.13) respectively). For detection of glucose concentrations < 2.6 mmol/l, the Precision glucometer had the highest sensitivity (96.4%) and negative predictive value (90%). For lower glucose concentrations (< 2.0 mmol/l), the Glucotrend glucometer performed even better (sensitivity 92.3%, negative predictive value 96.3%).

Conclusion: Point of care devices should have good precision in the low glucose concentration range, sensitivity, and accuracy for early detection of neonatal hypoglycaemia. None of the five glucometers was satisfactory as the sole measuring device. The Glucotrend and Precision glucometers have the greatest sensitivity and negative predictive value. However, confirmation with laboratory measurements of plasma glucose and clinical assessment are still of the utmost importance.

Low blood glucose is common in newborn infants. Affected infants usually have no symptoms and are therefore easily missed. Prolonged hypoglycaemia may result in long term adverse neurodevelopmental outcome.4-7 However, screening all newborn babies would be invasive. The yield is low and not cost effective. Therefore, in 1993, the American Academy of Pediatrics recommended selective testing for high risk cases. Screening for hypoglycaemia and early feeding were recommended only for infants with risk factors, such as intrauterine growth retardation and infants of maternal gestational diabetes.4

The optimum method for measuring plasma glucose is the hexokinase method. As it is usually performed in the main laboratory, results are not available quickly enough for timely appropriate treatment. Therefore ‘point of care’ devices (reflectance glucometers) are often used for measurement of whole blood glucose concentration in nursery and neonatal intensive care units. Low blood glucose concentration is then confirmed in the main laboratory.

Unfortunately, glucometer measurement is problematic. This is especially true for newborn babies. Currently used glucometers were initially developed for glucose monitoring in adult patients with diabetes. Many studies have shown that their results correlate well with laboratory measured plasma glucose in the normoglycaemic and hyperglycaemic range, but are not satisfactory in the lower range. However, our main concern in newborn babies is the low blood glucose range.

In 1994, the American Diabetic Association (ADA) recommended that a glucometer should achieve a total error (system + user) of less than 10% for the plasma glucose concentration range 1.6–22.2 mmol/l (30–400 mg/dl).8 It was also ascertained by the US National Committee for Clinical Laboratory Standards (NCCLS) in 1994 that for glucose concentrations less than 5.5 mmol/l (100 mg/dl), discrepancies should be no more than 0.83 mmol/l (15 mg/dl).9

The haemoglobin concentration and packed cell volume in newborns also affect the results of whole blood Glucostix measurement. Anaemia falsely raises and polycthaemia falsely depresses glucometer readings. In general, whole blood glucose concentrations are 10–15% lower than plasma glucose measurements.

Cornblath et al.10 recommended operational thresholds at which clinicians should consider intervention. This threshold varies with gestation, breast feeding, and the presence of risk factors. If the plasma glucose concentration is less than 2.0 mmol/l (36 mg/dl), close surveillance and intervention should be considered. For preterm infants, a higher cut off value of 2.6 mmol/l (47 mg/dl) was suggested, as it may be correlated with abnormal neuromotor and intellectual performance at 18 months of age. Therefore the practice in our hospital is to screen for whole blood glucose using a glucometer in infants with risk factors. This is subsequently confirmed by plasma glucose measurement if it is less than 2.6 mmol/l.11

There are many different types of glucometers available for point of care glucose measurement. Various studies have evaluated their accuracies.12-20 The Reflolux S glucometer was the one commonly used in our neonatal unit, although, in our experience, it usually underestimated the true plasma glucose concentration.

Abbreviations: ADA, American Diabetic Association; NCCLS, National Committee for Clinical Laboratory Standards; NPV, negative predictive value; PPV, positive predictive value.
Evaluation of glucometers for hypoglycaemia diagnosis

corresponding glucose mean. The limits of agreement plasma glucose concentration was then plotted against the difference (d) discrepancies were also calculated according to the standard mean difference was also calculated. The total error and the glucometer reading (residuals); the mean (SD) of the differences between the plasma glucose concentration and the laboratory reading was set at less than 5.5 mmol/l (table 1).

RESULTS

Over a period of 10 months, a total of 101 specimens had been collected from 71 newborns (57 in phase I, 44 in phase II). The median gestational age was 38 weeks (range 36–41). The measurements were performed at a median age of 1 day (range 0–3).

According to the ADA standard, none of the glucometers tested were satisfactory. Those that performed better (Glucotrend and Precision) had only 51% and 46.5% of tests that achieved a total error of less than 10%. However, these glucometers could achieve (94.5% and 86.0% respectively) the recommendation of NCCLS that measurement discrepancies should be less than 0.83 mmol/l for detecting glucose concentrations less than 5.5 mmol/l (table 1).

Only two measurements were indicated as “low” by the Reflolux S glucometer. None were found with the other glucometers tested. Using the method of residuals and the Bland and Altman plot, the Reflolux S glucometer usually underestimated the plasma glucose concentrations especially in the range 2.5–3.5 mmol/l. Their mean differences were 0.34 mmol/l (95% CI –0.64 to –0.21; p < 0.01) in phase I and 0.27 mmol/l (95% CI –0.42 to –0.12; p < 0.01) in phase II. The Advantage glucometer usually overestimated, with a mean difference (d) of 1.07 mmol/l (95% CI 0.21 to 0.59; p < 0.01). This occurred at all ranges of low blood glucose concentration studied. For the Glucotrend, Precision, and Elite XL glucometers, there were no significant differences from the laboratory measurements. Their mean differences were 0.17 mmol/l (95% CI –0.79 to 0.21; p = 0.37); –0.12 mmol/l (95% CI –0.27 to 0.34; p = 0.13), and 0.24 mmol/l (95% CI –0.73 to 0.55; p = 0.13) respectively (table 1).

When it was used as a screening device with confirmation by laboratory plasma glucose, the “low” measurements were also included in the statistical calculations. The Precision glucometer had the best sensitivity (96.4%) and NPV (90%) in the detection of neonatal hypoglycaemia (< 2.6 mmol/l). The Glucotrend glucometer was the second best with a sensitivity of 83.3% and NPV of 82.1%. For severe hypoglycaemia (< 2.0 mmol/l), Glucotrend performed even better; the sensitivity was 92.3% and NPV 96.3% (table 2).

<table>
<thead>
<tr>
<th>Glucometer</th>
<th>Mean</th>
<th>SD</th>
<th>95% CI</th>
<th>Percentage with total error &lt; 10% (ADA)</th>
<th>Percentage with discrepancy &lt; 0.83 mmol/l (NCCLS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucotrend</td>
<td>0.168</td>
<td>0.876</td>
<td>–0.79 to 0.21</td>
<td>51.0</td>
<td>94.5</td>
</tr>
<tr>
<td>Advantage</td>
<td>1.067</td>
<td>2.280</td>
<td>0.21 to 0.59</td>
<td>20.0</td>
<td>81.5</td>
</tr>
<tr>
<td>Reflolux S</td>
<td>–0.344</td>
<td>0.919</td>
<td>–0.64 to –0.21</td>
<td>26.3</td>
<td>68.4</td>
</tr>
<tr>
<td>Phase II</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elite XL</td>
<td>0.241</td>
<td>1.004</td>
<td>–0.73 to 0.55</td>
<td>38.1</td>
<td>85.7</td>
</tr>
<tr>
<td>Precision</td>
<td>–0.116</td>
<td>0.488</td>
<td>–0.27 to 0.34</td>
<td>46.5</td>
<td>86.0</td>
</tr>
<tr>
<td>Reflolux S</td>
<td>–0.268</td>
<td>0.496</td>
<td>–0.42 to 0.12</td>
<td>29.5</td>
<td>88.6</td>
</tr>
</tbody>
</table>

#### Statistical analysis

The SPSS program (version 11.5) was used for statistical analysis. The method of residuals was used to compare the differences between the plasma glucose concentration and the glucometer reading (residuals); the mean (SD) of the mean difference was also calculated. The total error and discrepancies were also calculated according to the standard recommendations by ADA and NCCLS. The difference (d) between the glucometer reading and the laboratory measured plasma glucose concentration was then plotted against the corresponding glucose mean. The limits of agreement (d-2SD, d+2SD) were also calculated. Lastly, as our threshold for plasma glucose confirmation was set at less than 2.6 mmol/l (47 mg/dl), the sensitivity, specificity, positive and negative predictive values (PPV and NPV) for detection of plasma glucose less than 2.6 mmol/l (47 mg/dl) and 2.0 mmol/l (36 mg/dl) were determined. The glucometer data displayed as “low” were not included in the calculation of mean difference and standard deviation, but were included in the sensitivity, specificity, PPV, and NPV calculations.
DISCUSSION

Many new glucometers have recently become available for blood glucose screening and are claimed to be good for use in newborn infants. Although many studies have been performed to determine the accuracy of point of care devices for measuring blood glucose concentrations, this study concentrated on the low glucose range, which is of most concern in the neonate. In our experience, the Reflolux S glucometer usually underestimates plasma glucose concentrations. Our results confirm this, showing a mean difference of 0.27–0.34 (SD 0.50–0.92). Therefore we decided to use it to screen for low values and then to test two newer glucometers when the value needed to be confirmed.

To simulate the real clinical situation, we did not check the packed cell volume in every case, only if anaemia or polycythaemia was clinically suspected. This should seldom miss

Table 2  Sensitivity, specificity, and positive and negative predictive values of glucometers for detection of hypoglycaemia (<2.6 and <2.0 mmol/l)

<table>
<thead>
<tr>
<th>Hypoglycaemia &lt;2.6 mmol/l</th>
<th>Hypoglycaemia &lt;2.0 mmol/l</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sensitivity (%)</td>
</tr>
<tr>
<td>Phase I</td>
<td></td>
</tr>
<tr>
<td>Glucotrend</td>
<td>83.3</td>
</tr>
<tr>
<td>Advantage</td>
<td>46.7</td>
</tr>
<tr>
<td>Reflolux S</td>
<td>100</td>
</tr>
<tr>
<td>Phase II</td>
<td></td>
</tr>
<tr>
<td>Elite XL</td>
<td>65.5</td>
</tr>
<tr>
<td>Precision</td>
<td>96.4</td>
</tr>
<tr>
<td>Reflolux S</td>
<td>100</td>
</tr>
</tbody>
</table>
cases of polycythaemia which may seriously affect the whole blood glucose measurement.

According to the ADA recommendation in 1994, none of the five glucometers could achieve a total error (system + user) of less than 10% ranging from 1.6 to 22.2 mmol/L. According to the NCCLS standard, the Glucotrend gluometer performed satisfactorily in more than 90% of cases, and the other glucometers in more than 85% of cases.

The Advantage gluometer usually overestimated plasma glucose in all ranges, and the Refloux S glucometer underestimated plasma glucose concentrations. A similar study on the Advantage gluometer also showed an overestimation of 0.7 mmol/l (SD 0.62). Our results indicate that the performance of the Advantage gluometer was even poorer in all ranges of low blood glucose. Both situations are unsatisfactory, as they would result in either a genuine hypoglycaemic case being missed or overtreatment. The Glucotrend and Precision glucometers showed the smallest differences from plasma glucose values.

Our results show that none of the five glucometers should be used alone for blood glucose measurement. However, if used as the initial screening device followed by confirmation by laboratory measured plasma glucose, a high sensitivity and NPV in detecting glucose concentrations less than 2.6 mmol/l (our operation threshold) and less than 2.0 mmol/l (more severe hypoglycaemia) are the most important. We found that the Glucotrend and Precision glucometers had the highest sensitivity and NPV.

**CONCLUSION**

A good screening device for neonatal hypoglycaemia should have good precision in the low concentration range and high sensitivity and NPV. We conclude that none of the five glucometers tested was satisfactory as the sole device for diagnosing neonatal hypoglycaemia. Although the Glucotrend and Precision glucometers had the highest sensitivity and NPV in detecting hypoglycaemia, confirmation with laboratory measurements of plasma glucose and clinical assessment of the infant are still of the utmost importance. Until other non-invasive (for example, near infrared spectroscopy) or continuous (for example, subcutaneous microdialysis) monitoring techniques are commonly available, screening with an appropriate bedside glucometer and subsequent plasma glucose confirmation will be the practical choice.

**Authors’ affiliations**

H T Ho, W K Y Yeung, B W Y Young, Department of Paediatrics and Adolescent Medicine, Pamela Youde Nethersole Eastern Hospital, Hong Kong SAR, China

**REFERENCES**

6. National Committee for Clinical Laboratory Standards. Ancillary (bedside) blood glucose testing acute and chronic care facilities; approved guidelines. NCCLS 1994; C38DA.
17. Royal College of Pathologists of Australasia (RCPA). Quality Assurance Program 2003: General Serum Chemistry and Therapeutic Drugs Program.